Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (59,501,016)	$ (67,197,746)
Change in value of derivatives	(233,052)	(2,446,403)
Acquired in-process research and development		10,142,786
Stock-based compensation	7,547,967	6,706,009
Depreciation and amortization	2,416,461	1,480,656
Amortization of note premiums	201,346	945,114
Changes in operating assets and liabilities:
Prepaid expenses and Other Current Assets	(887,426)	(3,522,763)
Accounts payable	913,664	2,328,360
Accrued expenses	(4,728,300)	(2,155,033)
Other	24,249	31,639
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(54,246,107)	(53,687,381)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(1,147,748)	(1,135,651)
Proceeds from sale of fixed assets		500
Proceeds from sale of marketable securities	16,308,000	19,411,146
Cash paid for acquisitions		(10,000,000)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	15,160,252	8,275,995
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital leases and notes payable	(162,824)	(160,162)
Payments of taxes for net share settled restricted stock unit issuances	(634,187)
Proceeds from the exercise of warrants and stock options	2,285,055	313,751
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	1,488,044	153,589
NET INCREASE (DECREASE) IN CASH	(37,597,811)	(45,257,797)
CASH AT BEGINNING OF PERIOD	81,214,354	132,510,610
CASH AT END OF PERIOD	43,616,543	87,252,813
Supplementary disclosures:
Interest paid	(8,906)	(11,153)
Property and Equipment purchased through tenant improvement allowance financing	(4,849,360)
Income Tax Credits Refunded	1,365,288
Income Taxes Paid	$ (2,400)	(2,400)
Common Stock issued to Novartis for asset acquisition		$ (25,000,000)